Spontaneous and secondary bacterial peritonitis in cirrhotic patients with ascites;Spontan-bakterielle und sekundäre Peritonitis bei Patienten mit Leberzirrhose und Aszites

Zentralblatt fur Chirurgie - Zeitschrift fur Allgemeine, Viszeral- und Gefasschirurgie

Volumn 139, Issue 2, 2014, Pages 160-167

  Bruns, T ^a   Stallmach, A ^a  

^a Klinik für Innere Medizin II des Universitätsklinikums Jena Abteilung für Gastroenterologie Hepatologie und Infektiologie   (Germany)

Author keywords

infection; liver failure; peritonitis

Indexed keywords

CEPHALOSPORIN DERIVATIVE;

ANTIBIOTIC PROPHYLAXIS; ASCITES; BACTERIAL INFECTIONS; BACTERIAL TRANSLOCATION; COMPLICATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFECTS; HUMAN; LIVER CIRRHOSIS; MICROBIOLOGY; PERITONITIS;

ANTIBIOTIC PROPHYLAXIS; ASCITES; BACTERIAL INFECTIONS; BACTERIAL TRANSLOCATION; CEPHALOSPORINS; HUMANS; LIVER CIRRHOSIS; PERITONITIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84899952229     PISSN: 0044409X     EISSN: 14389592     Source Type: Journal    
DOI: 10.1055/s-0031-1283815     Document Type: Article

References (64)

1. Cazzaniga M., Dionigi E., Gobbo G. et al. The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in-hospital outcome. J Hepatol: 2009; 51 475 482
2. th meeting of the International Ascites Club. Gut: 2005; 54 718 725
3. Gomez F., Ruiz P., Schreiber A. D. Impaired function of macrophage Fc gamma receptors and bacterial infection in alcoholic cirrhosis. N Engl J Med: 1994; 331 1122 1128
4. Fiuza C., Salcedo M., Clemente G. et al. In vivo neutrophil dysfunction in cirrhotic patients with advanced liver disease. J Infect Dis: 2000; 182 526 533
5. Lin C-Y, Tsai I-F, Ho Y-P et al. Endotoxemia contributes to the immune paralysis in patients with cirrhosis. J Hepatol: 2007; 46 816 826
6. Bruns T., Peter J., Hagel S. et al. The augmented neutrophil respiratory burst in response to Escherichia coli is reduced in liver cirrhosis during infection. Clin Exp Immunol: 2011; 164 346 356
7. Borzio M., Salerno F., Piantoni L. et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis: 2001; 33 41 48
8. Arvaniti V., D'Amico G., Fede G. et al. Infections in Patients With Cirrhosis Increase Mortality Four-Fold and Should Be Used in Determining Prognosis. Gastroenterology: 2010; 139 1246.e5 1256.e5
9. Fleming K. M., Aithal G. P., Card T. R. et al. All-cause mortality in people with cirrhosis compared with the general population: a population-based cohort study. Liver Int: 2011; 10.1111/j.1478-3231.2011.02517.x [in press]
10. D'Amico G., Garcia-Tsao G., Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol: 2006; 44 217 231
11. Sersté T., Melot C., Francoz C. et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology: 2010; 52 1017 1022
12. Bruns T., Sachse S., Straube E. et al. Identification of bacterial DNA in neutrocytic and non-neutrocytic cirrhotic ascites by means of a multiplex polymerase chain reaction. Liver Int: 2009; 29 1206 1214
13. Bruns T., Peter J., Reuken P. A. et al. NOD2 gene variants are a risk factor for culture-positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis. Liver Int: 2011; 10.1111/j.1478-3231.2011.02561.x [in press]
14. Chang C. S., Yang S. S., Kao C. H. et al. Small intestinal bacterial overgrowth versus antimicrobial capacity in patients with spontaneous bacterial peritonitis. Scand J Gastroenterol: 2001; 36 92 96
15. Chang C. S., Chen G. H., Lien H. C. et al. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology: 1998; 28 1187 1190
16. Scarpellini E., Valenza V., Gabrielli M. et al. Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed? Am J Gastroenterol: 2010; 105 323 327
17. Chavez-Tapia N. C., Barrientos-Gutierrez T., Tellez-Avila F. et al. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review. Aliment Pharmacol Ther: 2011; 34 509 518
18. Runyon B. A. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology: 1986; 91 1343 1346
19. García-Díaz M., Alcalde M., de Sande F. et al. Low protein concentration in cirrhotic ascites is related to low ascitic concentrations of immunoglobulins G and A. Eur J Gastroenterol Hepatol: 1995; 7 963 969
20. Runyon B. A., Morrissey R. L., Hoefs J. C. et al. Opsonic activity of human ascitic fluid: a potentially important protective mechanism against spontaneous bacterial peritonitis. Hepatology: 1985; 5 634 637
21. Trikudanathan G., Israel J., Cappa J. et al. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients - a systematic review and meta-analysis. Int J Clin Pract: 2011; 65 674 678
22. Senzolo M., Cholongitas E., Burra P. et al. beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int: 2009; 29 1189 1193
23. Nischalke H. D., Berger C., Aldenhoff K. et al. Toll-like receptor (TLR) 2 promotor and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. J Hepatol: 2011; 55 05 1010 1016
24. Appenrodt B., Grünhage F., Gentemann M. G. et al. Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology: 2010; 51 1327 1333
25. Bruns T., Reuken P. A., Fischer J. et al. Further evidence for the relevance of TLR2 gene variants in spontaneous bacterial peritonitis. J Hepatol: 2011; 10.1016/j.jhep.2011.09.010 [in press]
26. Guarner-Argente C., Sánchez E., Vidal S. et al. Toll-like receptor 4 D299G polymorphism and the incidence of infections in cirrhotic patients. Aliment Pharmacol Ther: 2010; 31 1192 1199
27. Ginès P., Angeli P., Lenz K. et al. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol: 2010; 53 397 417
28. Gerbes A. L., Gülberg V., Sauerbruch T. et al. [German S 3-guideline ascites, spontaneous bacterial peritonitis, hepatorenal syndrome]. Z Gastroenterol: 2011; 49 749 779
29. Titó L., Rimola A., Ginès P. et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology: 1988; 8 27 31
30. Ginés P., Rimola A., Planas R. et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology: 1990; 12 716 724
31. Soriano G., Guarner C., Teixidó M. et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology: 1991; 100 477 481
32. Singh N., Gayowski T., Yu V. L. et al. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med: 1995; 122 595 598
33. Rolachon A., Cordier L., Bacq Y. et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology: 1995; 22 1171 1174
34. Fernández J., Ruiz del Arbol L, Gómez C. et al. Norfloxacin vs. ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology: 2006; 131 1049 1056
35. Llach J., Rimola A., Navasa M. et al. Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration. Hepatology: 1992; 16 724 727
36. Guarner C., Solà R., Soriano G. et al. Risk of a first community-acquired spontaneous bacterial peritonitis in cirrhotics with low ascitic fluid protein levels. Gastroenterology: 1999; 117 414 419
37. Fernández J., Navasa M., Planas R. et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology: 2007; 133 818 824
38. Terg R., Fassio E., Guevara M. et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. J Hepatol: 2008; 48 774 779
39. Angeli P., Guarda S., Fasolato S. et al. Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. Aliment Pharmacol Ther: 2006; 23 75 84
40. Terg R., Cobas S., Fassio E. et al. Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter, randomized study. J Hepatol: 2000; 33 564 569
41. Navasa M., Follo A., Llovet J. M. et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology: 1996; 111 1011 1017
42. Aparicio J. R., Such J., Pascual S. et al. Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: clinical consequences. J Hepatol: 1999; 31 277 283
43. Ortiz J., Vila M. C., Soriano G. et al. Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients. Hepatology: 1999; 29 1064 1069
44. Fernández J., Navasa M., Gómez J. et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology: 2002; 35 140 148
45. Concepción M., Poca M., Gordillo J. et al. Evolution Of Antibiotic Susceptibility Of Bacteria Causing Spontaneous Bacterial Peritonitis: A 9-Year Study (Abstract). J Hepatol: 2011; 54 01 380 380
46. Cheong H. S., Kang C-I, Lee J. A. et al. Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial peritonitis in patients with liver cirrhosis. Clin Infect Dis: 2009; 48 1230 1236
47. Follo A., Llovet J. M., Navasa M. et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology: 1994; 20 1495 1501
48. Sort P., Navasa M., Arroyo V. et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med: 1999; 341 403 409
49. Soriano G., Castellote J., Alvarez C. et al. Secondary bacterial peritonitis in cirrhosis: a retrospective study of clinical and analytical characteristics, diagnosis and management. J Hepatol: 2010; 52 39 44
50. Akriviadis E. A., Runyon B. A. Utility of an algorithm in differentiating spontaneous from secondary bacterial peritonitis. Gastroenterology: 1990; 98 127 133
51. Runyon B. A., Hoefs J. C. Ascitic fluid analysis in the differentiation of spontaneous bacterial peritonitis from gastrointestinal tract perforation into ascitic fluid. Hepatology: 1984; 4 447 450
52. Wu S. S., Lin O. S., Chen Y. Y. et al. Ascitic fluid carcinoembryonic antigen and alkaline phosphatase levels for the differentiation of primary from secondary bacterial peritonitis with intestinal perforation. J Hepatol: 2001; 34 215 221
53. Hartl W., Kuppinger D., Vilsmaier M. Sekundäre Peritonitis. Zentralbl Chir: 2011; 136 11 17
54. Pacelli F., Doglietto G. B., Alfieri S. et al. Prognosis in intra-abdominal infections. Multivariate analysis on 60 patients. Arch Surg: 1996; 131 641 645
55. Wacha H., Hau T., Dittmer R. Peritonitis Study Group et al. Risk factors associated with intraabdominal infections: a prospective multicenter study. Langenbecks Arch Surg: 1999; 384 24 32
56. Ziser A., Plevak D. J., Wiesner R. H. et al. Morbidity and mortality in cirrhotic patients undergoing anesthesia and surgery. Anesthesiology: 1999; 90 42 53
57. Teh S. H., Nagorney D. M., Stevens S. R. et al. Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology: 2007; 132 1261 1269
58. van Till J. WO, van Veen S. Q., van Ruler O. et al. The innate immune response to secondary peritonitis. Shock: 2007; 28 504 517
59. Dunn D. L., Barke R. A., Ahrenholz D. H. et al. The adjuvant effect of peritoneal fluid in experimental peritonitis. Mechanism and clinical implications. Ann Surg: 1984; 199 37 43
60. Caralis P. V., Sprung C. L., Schiff E. R. Secondary bacterial peritonitis in cirrhotic patients with ascites. South Med J: 1984; 77 579 583
61. Wong P. F., Gilliam A. D., Kumar S. et al. Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adults. Cochrane Database Syst Rev: 2005; CD004539
62. van Ruler O., Kiewiet J. JS, van Ketel R. J. et al. Initial microbial spectrum in severe secondary peritonitis and relevance for treatment. Eur J Clin Microbiol Infect Dis: 2011; 10.1007/s10096-011-1357-0 [in press]
63. Seguin P., Fédun Y., Laviolle B. et al. Risk factors for multidrug-resistant bacteria in patients with post-operative peritonitis requiring intensive care. J Antimicrob Chemother: 2010; 65 342 346
64. de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol: 2010; 53 762 768